GLTO Stock Risk & Deep Value Analysis
GLTO
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on GLTO
We analyzed GLTO using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GLTO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when GLTO moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈GLTO Performance Overview3yr weekly
Unlock GLTO Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
GLTO Quality Rating
GLTO Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About GLTO (GLTO)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$1.73B
GLTO Deep Value Analysis
GLTO Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
GLTO Red Flags & Warning Signs
- ⚠
Negative or inconclusive results from preclinical studies
- ⚠
Delays in IND filing or clinical trial initiation
- ⚠
Increased cash burn rates without offsetting financing
Unlock GLTO Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
GLTO Financial Health Metrics
Market Cap
$1.73B
P/E Ratio
520.00
Profit Margin
11.00%
Debt-to-Equity
0.41
Dividend Yield
1.30%
Beta (Volatility)
1.56
Earnings Per Share
$-12.01
GLTO Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding. If pipeline assets progress successfully through clinical trials and gain regulatory approval, their IP protection will solidify the moat.
Moat Sources
1 Identified
The moat's durability hinges entirely on the success of drug development and the robustness of patent protection. If drugs fail trials or face patent challenges, the moat could quickly erode.
GLTO Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
GLTO Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings report (Estimated mid-May 2026)
- •Updates on lead asset's preclinical development or IND filing status
Medium-Term (6-18 months)
- •Initiation of Phase 1 or 1/2 clinical trials for acquired pipeline assets
- •Potential strategic partnership for pipeline development or commercialization
Long-Term (18+ months)
- •Positive Phase 2 clinical trial readouts for lead drug candidates
- •Expansion of pipeline through new acquisitions or internal development
Catalysts & Growth Drivers
Sign up free to see growth catalysts
GLTO Bull Case: What Could Go Right
- ✓
Positive clinical trial data readouts (Phase 1/2/3)
- ✓
Announcement of new strategic partnerships or licensing agreements
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for GLTO (GLTO)?
As of April 20, 2026, GLTO has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of GLTO?
GLTO's market capitalization is approximately $1.7B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does GLTO use?
GLTO is the ticker symbol for GLTO. The company trades on the NCM.
What is the risk level for GLTO stock?
Our analysis rates GLTO's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GLTO?
GLTO currently has a price-to-earnings (P/E) ratio of 520.0. This is above the market average, suggesting the stock may be priced for high growth expectations.
Does GLTO pay a dividend?
Yes, GLTO pays a dividend with a current yield of approximately 1.30%.
Is GLTO's revenue growing?
GLTO has reported revenue growth of 7.6%. The company is growing at a moderate pace.
Is GLTO stock profitable?
GLTO has a profit margin of 11.0%. The company is profitable but margins are modest.
How often is the GLTO DVR analysis updated?
Our AI-powered analysis of GLTO is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.